Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 14,335 shares at $263.23 ($2.6M) on 2021-11-10, disclosed to the SEC on 2021-11-12.
Open-market sale of $2.6M RGEN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.12 | 4,783 | $125K | 4.7% |
| 2 | $259.75 | 462 | $120K | 4.5% |
| 3 | $259.75 | 462 | $120K | 4.5% |
| 4 | $261.10 | 236 | $62K | 2.3% |
| 5 | $261.10 | 236 | $62K | 2.3% |
| 6 | $262.28 | 1,038 |
| $272K |
| 10.3% |
| 7 | $262.28 | 1,038 | $272K | 10.3% |
| 8 | $263.23 | 1,119 | $295K | 11.1% |
| 9 | $263.23 | 1,119 | $295K | 11.1% |
| 10 | $264.21 | 336 | $89K | 3.4% |
| 11 | $264.21 | 336 | $89K | 3.4% |
| 12 | $265.27 | 488 | $129K | 4.9% |
| 13 | $265.27 | 488 | $129K | 4.9% |
| 14 | $266.72 | 486 | $130K | 4.9% |
| 15 | $266.72 | 486 | $130K | 4.9% |
| 16 | $267.75 | 349 | $93K | 3.5% |
| 17 | $267.75 | 349 | $93K | 3.5% |
| 18 | $269.94 | 255 | $69K | 2.6% |
| 19 | $269.94 | 255 | $69K | 2.6% |
| 20 | $271.28 | 14 | $4K | 0.1% |
| Total | $184.57 avg | 14,335 | $2.6M | 100% |
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |